TELA

TELA Bio, Inc. (TELA) | Rumor.io

TELA Bio

TELA

Attention (50-day avg)0%

Attention rank (50-day avg)#3,003

Bullish sentiment (50-day avg)1%

Price to earnings ratio-1.48

Market capitalization55.5M

Earnings per share-0.77

Dividend yield (TTM)—

Revenue (annual)80.3M

Net income (annual)-38.8M

Social

What share of all stock conversation is about TELA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Mar 21

TELA Bio's stock price has dropped 43% after reporting weak Q4 growth and high sales turnover, with some analysts downgrading their target price.
Piper Sandler has adjusted its stance on TELA Bio to Neutral with a target price of $2, and Canaccord Genuity has updated its rating to Buy with a target price of $12.
TELA Bio's Q4 financial results showed weak growth, and the company may need to raise another round of capital, with some analysts expressing concerns about the company's operating expenses and potential cash burn.

Generated by AI

Sentiment

Of the messages about TELA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	0% -100	18.44% -70.3
Bearish	—	—	100% new	81.56% +70.3

Topics

Of the messages about TELA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	4.62%
Announcements	—	—	—	41.54%
Controversies	—	—	—	3.08%
Earnings	—	—	—	47.69%
Macro	—	—	—	0%
Technical Analysis	—	—	—	3.08%

Community

Of the messages about TELA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	30.86%
Newcomers	—	—	100%	69.14%

Regulars· Apr 19

TELA Bio has priced a $45M offering of 4.8M shares at $9.50/share, which is expected to be delivered in one month.
Regular investors are focused on the company's ability to deliver its upcoming earnings report, with a critical deadline one month from now.
The stock has declined in premarket trading, following the announcement of the public offering of common stock.

Newcomers· Nov 8

TELA Bio, Inc. priced its IPO at $13.00 per share, 7% below the low end of its expected price range.
The company opened at $13.75, gaining 5.8% at first trade, and was one of the weaker IPOs of the week.
The $TELA IPO is seen as a cheap, category-innovation med-tech opportunity, with some traders setting a price target of $15.

Generated by AI

News

TELA Bio Announces COO / CFO Transition and Strategic Cost Reduction Initiative

Company to reduce annual operating expenses by $17.0 million or 18% as part of broader efficiency programMALVERN, Pa., Aug. 31, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio” or the “Company”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that Roberto Cuca, Chief Operating Officer and Chief Financial Officer, will step down from the role effective today. “On behalf of the Board and management team, I woul

1mo agoYahoo! Finance Canada

Tela Bio CEO Heather Getz buys $8,311 in company stock

1mo agoInvesting.com

TELA Bio (TELA) Q2 2026 Earnings Call Transcript

Detailed price information for Tela Bio Inc (TELA-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Also Discussed

Investors talking about TELA also mention

#	Name	Attention
1	CUTR - Cutera, Inc.	——
2	Mereo BioPharma Group plc ADRMREO	0.01%-0.01
3	Tiziana Life Sciences LtdTLSA	0%0
4	NOGN - Nogin, Inc.	——
5	DCPH - Deciphera Pharmaceuticals, Inc.	——
6	Avita Medical, Inc.RCEL	0%0
7	VAPO - Vapotherm, Inc.	——
8	SWTX - SpringWorks Therapeutics, Inc.	——
9	VinFast Auto Ltd.VFS	0%new
10	Journey Medical Corp. Common StockDERM	0%new

TELA Bio, Inc.

Healthcare
Medical Devices

TELA Bio, Inc. is a commercial-stage medical technology company focused on soft-tissue reconstruction solutions for surgeons and healthcare providers. The company develops and markets reinforced tissue matrix products designed for hernia repair, abdominal wall reconstruction, and plastic and reconstructive surgery, with an emphasis on preserving and restoring the patient’s own anatomy. Its OviTex portfolio includes products for open, laparoscopic, and robotic procedures, as well as configurations tailored to different surgical needs in general surgery and reconstructive care. TELA Bio also supports applications that aim to reduce reliance on permanent synthetic materials while leveraging the body’s natural healing response. Headquartered in Malvern, Pennsylvania, TELA Bio serves the medical device market through products that address unmet needs in modern soft-tissue repair.

Website

Location

1 Great Valley Parkway

Malvern, PA, 19355

United States

Social

What share of all stock conversation is about TELA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Mar 21

TELA Bio's stock price has dropped 43% after reporting weak Q4 growth and high sales turnover, with some analysts downgrading their target price.
Piper Sandler has adjusted its stance on TELA Bio to Neutral with a target price of $2, and Canaccord Genuity has updated its rating to Buy with a target price of $12.
TELA Bio's Q4 financial results showed weak growth, and the company may need to raise another round of capital, with some analysts expressing concerns about the company's operating expenses and potential cash burn.

Generated by AI

Sentiment

Of the messages about TELA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	0% -100	18.44% -70.3
Bearish	—	—	100% new	81.56% +70.3

Topics

Of the messages about TELA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	4.62%
Announcements	—	—	—	41.54%
Controversies	—	—	—	3.08%
Earnings	—	—	—	47.69%
Macro	—	—	—	0%
Technical Analysis	—	—	—	3.08%

Community

Of the messages about TELA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	30.86%
Newcomers	—	—	100%	69.14%

Regulars· Apr 19

TELA Bio has priced a $45M offering of 4.8M shares at $9.50/share, which is expected to be delivered in one month.
Regular investors are focused on the company's ability to deliver its upcoming earnings report, with a critical deadline one month from now.
The stock has declined in premarket trading, following the announcement of the public offering of common stock.

Newcomers· Nov 8

TELA Bio, Inc. priced its IPO at $13.00 per share, 7% below the low end of its expected price range.
The company opened at $13.75, gaining 5.8% at first trade, and was one of the weaker IPOs of the week.
The $TELA IPO is seen as a cheap, category-innovation med-tech opportunity, with some traders setting a price target of $15.

Generated by AI

TELA Bio

Social

Mar 21

Regulars· Apr 19

Newcomers· Nov 8

Tela Bio director Capper acquires $78,442 in company stock

Tela Bio CEO Heather Getz buys $8,311 in company stock

TELA Bio cuts 20% of workforce to reduce costs by $17M annually

TELA Bio Announces COO / CFO Transition and Strategic Cost Reduction Initiative

Tela Bio CEO Heather Getz buys $8,311 in company stock

TELA Bio (TELA) Q2 2026 Earnings Call Transcript

Also Discussed

TELA Bio, Inc.

Company Information

Location

Tela Bio director Capper acquires $78,442 in company stock

Tela Bio CEO Heather Getz buys $8,311 in company stock

TELA Bio cuts 20% of workforce to reduce costs by $17M annually

TELA Bio Announces COO / CFO Transition and Strategic Cost Reduction Initiative

Tela Bio CEO Heather Getz buys $8,311 in company stock

TELA Bio (TELA) Q2 2026 Earnings Call Transcript

Also Discussed

Social

Mar 21

Regulars· Apr 19

Newcomers· Nov 8